Previous 10 | Next 10 |
home / stock / phguf / phguf news
2023-08-06 02:54:01 ET Pharming Group N.V. (PHGUF) Q2 2023 Earnings Conference Call August 03, 2023 07:30 AM ET Company Participants Sijmen de Vries - CEO Anurag Relan - CMO Stephen Toor - CCO Jeroen Wakkerman - CFO Conference Call Participants Ch...
2023-08-04 06:36:21 ET Pharming Group N.V. press release ( OTCPK:PHGUF ): Q2 Revenue of $54.9M. cash and cash equivalents, including restricted cash, of US$194.1 million at the end of 2Q 2023, compared to US$186.2 million at end of 1Q 2023 For further det...
2023-05-11 14:44:06 ET Pharming Group N.V. (PHGUF) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Sijmen de Vries – Chief Executive Officer Anurag Relan – Chief Medical Officer Stephen Toor – Chief Commercial Of...
2023-05-11 10:05:51 ET Pharming Group N.V. ( OTCPK:PHGUF ): Q1 GAAP EPS of $0.02. Revenue of $42.5M (-8.8% Y/Y) misses by $6M . For further details see: Pharming Group N.V. GAAP EPS of $0.02, revenue of $42.5M misses by $6M
2023-03-27 05:45:26 ET The shares of Dutch biotech Pharming Group N.V. ( NASDAQ: PHAR ) added ~24% on Monday in the Amsterdam stock exchange on the announcement of U.S. approval for the rare immune disorder therapy Joenja co-developed with Novartis ( NVS ). The FDA...
2023-03-16 10:04:06 ET Pharming Group N.V. (PHGUF) Q4 2022 Earnings Call Transcript March 16, 2023 08:30 AM ET Company Participants Sijmen de Vries - Executive Director & Chief Executive Officer Anurag Relan - Chief Medical Officer Jeroen Wakkerman - Chief Fi...
2023-03-16 08:53:37 ET The following slide deck was published by Pharming Group N.V. in conjunction with their 2022 Q4 earnings call. For further details see: Pharming Group N.V. 2022 Q4 - Results - Earnings Call Presentation
Pharming announces first patient enrolled in pediatric clinical trial of leniolisib Canada NewsWire The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency LEIDEN, Netherlands ...
Pharming Group N.V. (PHGUF) Q3 2022 Earnings Conference Call October 27, 2022 7:30 AM ET Company Participants Sijmen de Vries - Chief Executive Officer Anurag Relan - Chief Medical Officer Jeroen Wakkerman - Chief Financial Officer Conference Call Participa...
The European Medicines Agency (EMA) validated Pharming's ( NASDAQ: PHAR ) application seeking approval of leniolisib to treat patients aged 12 years and older with activated phosphoinositide 3-kinase (PI3K) delta syndrome (APDS). The company's marketing authorisation a...
News, Short Squeeze, Breakout and More Instantly...
Pharming Group Nv Ord Company Name:
PHGUF Stock Symbol:
OTCMKTS Market:
Pharming Group Nv Ord Website:
Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2024 financial results, for the period ended June 30, on Thursday, August 1, 2024. ...
Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of June: Jefferies Healthcare Conference, New ...
Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved. The shareholders approved the proposa...